BillionToOne
More intelligent healthcare for all with single molecule diagnostics.
BillionToOne is a molecular diagnostics company developing single-molecule next-generation sequencing (smNGS) technology for prenatal screening and liquid biopsy. Their proprietary Quantitative Counting Templates (QCTs™) platform enables direct measurement of sparse disease-causing DNA fragments from a single blood draw. The company aims to make healthcare more accessible and actionable by advancing early disease detection.
BillionToOne's proprietary QCTs™ power their smNGS platform to quantify and directly measure sparse disease-causing DNA molecules from cell-free DNA in a blood sample.
Healthcare providers and patients seeking advanced prenatal screening and liquid biopsy diagnostics
Background.
- Status
- launched
- Business model
- unknown
- Company
- BillionToOne
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.